Ezurpimtrostat clinical trials
Also written GNS561.
How each study uses ezurpimtrostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ezurpimtrostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Genoscience Pharma (3) · Genfit (1) · University Hospital, Grenoble (1)
Studies
Open first, then newest update. How each study uses ezurpimtrostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated CholangiocarcinomaRecruitingPhase 1/2GenfitNCT05874414Written as GNS561 + Trametinib
- Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular CarcinomaTerminatedPhase 2University Hospital, GrenobleNCT05448677Written as Ezurpimtrostat
- Study of GNS561 in Patients With Liver CancerTerminatedPhase 1/2Genoscience PharmaNCT03316222Written as GNS561
- Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy VolunteersStatus unknownPhase 1Genoscience PharmaNCT05353894Written as GNS561 oral tablets and capsules
- A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) InfectionStatus unknownPhase 2Genoscience PharmaNCT04637828Written as GNS561
Codes
What other systems call ezurpimtrostat · ClinicalTrials.gg INT017325
- UNII (FDA) MS6LGW5JFKEZURPIMTROSTATOne source FDA
- NCI Thesaurus C184909EzurpimtrostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | MS6LGW5JFK | EZURPIMTROSTAT | One source FDA |
| NCI Thesaurus | C184909 | Ezurpimtrostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.